BETHESDA, Md., Oct. 21, 2016 /PRNewswire/ -- Northwest Biotherapeutics (
Pursuant to the agreement, the Company has agreed to sell to the investor up to 14 million shares of the Company's Common Stock at a purchase price of $0.38 per share.
The sale of the shares is expected to close on or about October 26, 2016, subject to satisfaction of customary closing conditions. Roth Capital Partners acted as the exclusive placement agent for the offering.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-213777), which was declared effective by the United States Securities and Exchange Commission ("SEC") on October 18, 2016. This press release shall not constitute an offer to sell or the...